These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 1807286)

  • 1. Monitoring DNA cytometric parameters during the course of chronic myelogenous leukemia.
    Kropff M; Chatelain R; Muller CP; Wagner A; Wenzler T; Böhmer H; Böcking A
    Anal Quant Cytol Histol; 1991 Dec; 13(6):433-9. PubMed ID: 1807286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Importance of DNA-cytometric parameters in the prediction of blast crisis in the course of chronic myelogenous leukemia].
    Kropff M; Wenzler T; Wagner A; Muller CP; Böcking A
    Verh Dtsch Ges Pathol; 1990; 74():126-9. PubMed ID: 1708569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of high risk patients in chronic myelogenous leukemia by DNA-image cytometry.
    Muller CP; Kropff M; Biesterfeld S; Chatelain R; Wagner A; Wohltmann D; Böcking A
    Anticancer Res; 1991; 11(2):617-23. PubMed ID: 2064316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
    Cohen MH; Johnson JR; Pazdur R
    Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic myelogenous leukemia: mechanisms underlying disease progression.
    Shet AS; Jahagirdar BN; Verfaillie CM
    Leukemia; 2002 Aug; 16(8):1402-11. PubMed ID: 12145676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia--potential clinical significance.
    Inokuchi K; Yamaguchi H; Tarusawa M; Futaki M; Hanawa H; Tanosaki S; Dan K
    Leukemia; 2002 Feb; 16(2):170-7. PubMed ID: 11840282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.
    Thota NK; Gundeti S; Linga VG; Coca P; Tara RP;
    Indian J Cancer; 2014; 51(1):5-9. PubMed ID: 24947087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The location of breakpoints within the breakpoint cluster region (bcr) of chromosome 22 in chronic myeloid leukemia.
    Eisenberg A; Silver R; Soper L; Arlin Z; Coleman M; Bernhardt B; Benn P
    Leukemia; 1988 Oct; 2(10):642-7. PubMed ID: 3172841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lineage involvement by BCR/ABL in Ph+ lymphoblastic leukemias: chronic myelogenous leukemia presenting in lymphoid blast vs Ph+ acute lymphoblastic leukemia.
    Anastasi J; Feng J; Dickstein JI; Le Beau MM; Rubin CM; Larson RA; Rowley JD; Vardiman JW
    Leukemia; 1996 May; 10(5):795-802. PubMed ID: 8656674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. bcr/abl mRNA in leukemic blasts of an unusual patient with acute lymphoblastic leukemia followed after 5-year remission by chronic myelogenous leukemia in blast crisis.
    Fujie H; Tsuchiya S; Morita S; Itano M; Yambe T; Ohasi Y; Minegishi N; Minegishi M; Satou T; Konno T
    Leukemia; 1994 Sep; 8(9):1592-5. PubMed ID: 8090037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib.
    Koh Y; Kim I; Yoon SS; Kim BK; Kim DY; Lee JH; Lee KH; Park E; Kim HJ; Sohn SK; Joo YD; Kim SJ; Chung J; Shin HJ; Kim SH; Kim CS; Song HS; Kim MK; Hyun MS; Ahn JS; Jung CW; Park S;
    Ann Hematol; 2010 Jul; 89(7):725-31. PubMed ID: 20179930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Molecular analysis of transformation into blast crisis in chronic myelogenous leukemia].
    Okabe M
    Hokkaido Igaku Zasshi; 1993 Mar; 68(2):237-50. PubMed ID: 8509066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic myeloid leukemia blast crisis arises from progenitors.
    Michor F
    Stem Cells; 2007 May; 25(5):1114-8. PubMed ID: 17218393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
    Phan CL; Megat Baharuddin PJ; Chin LP; Zakaria Z; Yegappan S; Sathar J; Tan SM; Purushothaman V; Chang KM
    Cancer Genet Cytogenet; 2008 Jan; 180(1):60-4. PubMed ID: 18068536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
    Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
    Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
    Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluorescence in situ hybridization (FISH) detection of trisomy 8 in myeloid cells in chronic myeloid leukemia (CML): a study of archival blood and bone marrow smears.
    Nguyen PL; Arthur DC; Litz CE; Brunning RD
    Leukemia; 1994 Oct; 8(10):1654-62. PubMed ID: 7934161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia].
    Liu XL; Zhou SY; Du QF; Zheng WY; Zhang S; Song LL; Xu B; Liu QF; Meng FY
    Ai Zheng; 2004 Apr; 23(4):421-5. PubMed ID: 15087031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors for prognosis of chronic myelocytic leukemia.
    Chen SS; Zhang HF; Xue WT; Li K; Wang P; Lui Y
    Chin Med J (Engl); 1993 Oct; 106(10):760-2. PubMed ID: 7913433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The proto-oncogene expression varies over the course of chronic myeloid leukemia.
    Vidović A; Janković G; Colović M; Tomin D; Perunicić M; Bila J; Marković O; Bosković D
    Hematology; 2008 Feb; 13(1):34-40. PubMed ID: 18534064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.